Login to Your Account



Abbvie completes $293M Singapore plant with biologics facility

By David Ho
Staff Writer

Wednesday, October 11, 2017

HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription